TNF and psoriatic arthritis: TIDI has also been developed for an economic model (and associated evidence syntheses) commissioned by NICE assessing the cost-effectiveness of tumor necrosis factor alpha (TNF-alpha) inhibitors (etanercept, infliximab, and adalimumab) when used in treatment of psoriatic arthritis [26].